CSF2 and autoimmune pulmonary alveolar proteinosis: This distinction is crucial for diagnosis and treatment, as recombinant GM-CSF therapy is effective in autoimmune PAP but unlikely to work in hPAP due to the underlying receptor dysfunction [9,11].